These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27529526)

  • 1. [Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].
    Stahmeyer JT; Rossol S; Bert F; Liersch S; Krauth C
    Z Gastroenterol; 2016 Aug; 54(8):760-9. PubMed ID: 27529526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
    Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
    Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
    Younossi ZM; Park H; Gordon SC; Ferguson JR; Ahmed A; Dieterich D; Saab S
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP205-11. PubMed ID: 27266950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    Stahmeyer JT; Rossol S; Liersch S; Guerra I; Krauth C
    PLoS One; 2017; 12(1):e0169401. PubMed ID: 28046099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
    Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
    J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
    Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
    Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
    J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
    Zanaga LP; Miotto N; Mendes LC; Stucchi RS; Vigani AG
    Braz J Med Biol Res; 2016 Oct; 49(11):e5504. PubMed ID: 27783808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
    J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Younossi ZM; Stepanova M; Nader F; Henry L
    J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.